These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 25042398)

  • 1. Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL).
    Rytting ME; Thomas DA; O'Brien SM; Ravandi-Kashani F; Jabbour EJ; Franklin AR; Kadia TM; Pemmaraju N; Daver NG; Ferrajoli A; Garcia-Manero G; Konopleva MY; Cortes JE; Borthakur G; Garris R; Cardenas-Turanzas M; Schroeder K; Jorgensen JL; Kornblau SM; Kantarjian HM
    Cancer; 2014 Dec; 120(23):3660-8. PubMed ID: 25042398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen.
    Rytting ME; Jabbour EJ; Jorgensen JL; Ravandi F; Franklin AR; Kadia TM; Pemmaraju N; Daver NG; Ferrajoli A; Garcia-Manero G; Konopleva MY; Borthakur G; Garris R; Wang S; Pierce S; Schroeder K; Kornblau SM; Thomas DA; Cortes JE; O'Brien SM; Kantarjian HM
    Am J Hematol; 2016 Aug; 91(8):819-23. PubMed ID: 27178680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen.
    Thomas D; O'Brien S; Faderl S; Ravandi F; Jabbour E; Pierce S; Cortes J; Kantarjian H
    Cancer; 2010 Oct; 116(19):4580-9. PubMed ID: 20572037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
    Vora A; Goulden N; Mitchell C; Hancock J; Hough R; Rowntree C; Moorman AV; Wade R
    Lancet Oncol; 2014 Jul; 15(8):809-18. PubMed ID: 24924991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is the BFM Regimen Feasible for the Treatment of Adult Acute Lymphoblastic Leukemia? A Retrospective Analysis of the Outcomes of BFM and Hyper-CVAD Chemotherapy in Two Centers.
    Alacacioglu I; Medeni SS; Ozsan GH; Payzin B; Sevindik OG; Acar C; Katgi A; Ozdemirkan F; Piskin O; Ozcan MA; Undar B; Demirkan F
    Chemotherapy; 2014; 60(4):219-23. PubMed ID: 25871894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.
    Larson RA; Dodge RK; Burns CP; Lee EJ; Stone RM; Schulman P; Duggan D; Davey FR; Sobol RE; Frankel SR
    Blood; 1995 Apr; 85(8):2025-37. PubMed ID: 7718875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric-like GIMEMA LAL-1308 trial.
    Testi AM; Canichella M; Vitale A; Piciocchi A; Guarini A; Starza ID; Cavalli M; De Propris MS; Messina M; Elia L; Moleti ML; Martino B; Luppi M; D'Aloisio M; Candoni A; Conter V; Fazi P; Vignetti M; Chiaretti S; Foà R
    Am J Hematol; 2021 Mar; 96(3):292-301. PubMed ID: 33284999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial.
    Jabbour E; Richard-Carpentier G; Sasaki Y; Konopleva M; Patel K; Roberts K; Gu Z; Wang F; Huang X; Sasaki K; Short NJ; Jain N; Ravandi F; Daver NG; Kadia TM; Alvarado Y; DiNardo CD; Issa GC; Pemmaraju N; Garcia-Manero G; Verstovsek S; Wang S; Khoury JD; Jorgensen J; Champlin R; Khouri I; Kebriaei P; Schroeder H; Khouri M; Mullighan CG; Takahashi K; O'Brien SM; Kantarjian H
    Lancet Haematol; 2020 Jul; 7(7):e523-e533. PubMed ID: 32589978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.
    Thomas DA; O'Brien S; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Ravandi F; Verstovsek S; Jorgensen JL; Bueso-Ramos C; Andreeff M; Pierce S; Garris R; Keating MJ; Cortes J; Kantarjian HM
    J Clin Oncol; 2010 Aug; 28(24):3880-9. PubMed ID: 20660823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Long-term destiny of adolescents and young adults with de novo acute lymphoblastic leukemia treated with a pediatric protocol type].
    López-Hernández MA; Alvarado-Ibarra M; Álvarez-Veral JL; Ortiz-Zepeda M; Guajardo-Leal ML; Cota-Range X
    Gac Med Mex; 2016; 152(5):439-443. PubMed ID: 27792701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot study of daunorubicin-augmented hyper-CVAD induction chemotherapy for adults with acute lymphoblastic leukemia.
    Kim SY; Park JH; Yoon SY; Cho YH; Lee MH
    Cancer Chemother Pharmacol; 2018 Feb; 81(2):393-398. PubMed ID: 29294168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyper-CVAD Compared With BFM-like Chemotherapy for the Treatment of Adult Acute Lymphoblastic Leukemia. A Retrospective Single-Center Analysis.
    El-Cheikh J; El Dika I; Massoud R; Charafeddine M; Mahfouz R; Kharfan-Dabaja MA; Bazarbachi A
    Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):179-185. PubMed ID: 27988194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adults with acute lymphoblastic leukemia and translocation (1;19) abnormality have a favorable outcome with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine chemotherapy.
    Garg R; Kantarjian H; Thomas D; Faderl S; Ravandi F; Lovshe D; Pierce S; O'Brien S
    Cancer; 2009 May; 115(10):2147-54. PubMed ID: 19298009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcomes of modified BFM-95 regimen in adults with newly diagnosed standard-risk acute lymphoblastic leukemia: a retrospective single-center study.
    Li C; Cai X; Chen X; Liang Y; Xia Z; Wang H
    Int J Hematol; 2019 Oct; 110(4):458-465. PubMed ID: 31321731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia.
    O'Brien S; Thomas DA; Ravandi F; Faderl S; Pierce S; Kantarjian H
    Cancer; 2008 Oct; 113(8):2097-101. PubMed ID: 18720356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.
    Kantarjian H; Thomas D; O'Brien S; Cortes J; Giles F; Jeha S; Bueso-Ramos CE; Pierce S; Shan J; Koller C; Beran M; Keating M; Freireich EJ
    Cancer; 2004 Dec; 101(12):2788-801. PubMed ID: 15481055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis.
    Sasaki K; Jabbour EJ; Ravandi F; Short NJ; Thomas DA; Garcia-Manero G; Daver NG; Kadia TM; Konopleva MY; Jain N; Issa GC; Jeanis V; Moore HG; Garris RS; Pemmaraju N; Cortes JE; O'Brien SM; Kantarjian HM
    Cancer; 2016 Dec; 122(23):3650-3656. PubMed ID: 27479888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Münster Study Group.
    Welte K; Reiter A; Mempel K; Pfetsch M; Schwab G; Schrappe M; Riehm H
    Blood; 1996 Apr; 87(8):3143-50. PubMed ID: 8605328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy of Hyper-CVAD/MA and CHALL-01 regimens in the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia patients under 60 years old].
    Huang AJ; Wang LB; Du J; Tang GS; Cheng H; Gong SL; Gao L; Qiu HY; Ni X; Chen J; Chen L; Zhang WP; Wang JM; Yang JM; Hu XX
    Zhonghua Xue Ye Xue Za Zhi; 2019 Aug; 40(8):625-632. PubMed ID: 31495127
    [No Abstract]   [Full Text] [Related]  

  • 20. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen.
    Weiser MA; Cabanillas ME; Konopleva M; Thomas DA; Pierce SA; Escalante CP; Kantarjian HM; O'Brien SM
    Cancer; 2004 Mar; 100(6):1179-85. PubMed ID: 15022284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.